Pharmaceutics (Dec 2022)

Standardization and Key Aspects of the Development of Whole Yeast Cell Vaccines

  • Anna Jéssica Duarte Silva,
  • Crislaine Kelly da Silva Rocha,
  • Antonio Carlos de Freitas

DOI
https://doi.org/10.3390/pharmaceutics14122792
Journal volume & issue
Vol. 14, no. 12
p. 2792

Abstract

Read online

In the context of vaccine development, improving antigenic presentation is critical for the activation of specific immune responses and the success of immunization, in addition to selecting an appropriate target. In this sense, different strategies have been developed and improved. Among them is the use of yeast cells as vehicles for the delivery of recombinant antigens. These vaccines, named whole yeast vaccines (WYVs), can induce humoral and cellular immune responses, with the additional advantage of dispensing with the use of adjuvants due to the immunostimulatory properties of their cell wall components. However, there are some gaps in the methodologies for obtaining and validating recombinant strains and vaccine formulations. The standardization of these parameters is an important factor for WYVs approval by regulatory agencies and, consequently, their licensing. This review aimed to provide an overview of the main parameters to consider when developing a yeast-based vaccine, addressing some available tools, and highlighting the main variables that can influence the vaccine production process.

Keywords